Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.14348/molcells.2021.0075

http://scihub22266oqcxt.onion/10.14348/molcells.2021.0075
suck pdf from google scholar
34059562!8245316!34059562
unlimited free pdf from europmc34059562    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid34059562      Mol+Cells 2021 ; 44 (6): 392-400
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis #MMPMID34059562
  • Lee E; Oh JE
  • Mol Cells 2021[Jun]; 44 (6): 392-400 PMID34059562show ga
  • It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humoral immunity to SARS-CoV-2 has been studied extensively, though there is still much that is unknown and controversial. Here, we introduce key discoveries on the humoral immune responses in COVID-19, including the immune dynamics of antibody responses and correlations with disease severity, neutralizing antibodies and their cross-reactivity, how long the antibody and memory B-cell responses last, aberrant autoreactive antibodies generated in COVID-19 patients, and the efficacy of currently available therapeutic antibodies and vaccines against circulating SARS-CoV-2 variants, and highlight gaps in the current knowledge.
  • |*Immunoglobulin Class Switching[MESH]
  • |Antibodies, Neutralizing/*biosynthesis/therapeutic use[MESH]
  • |Antibodies, Viral/biosynthesis[MESH]
  • |Antibody-Dependent Enhancement[MESH]
  • |Autoantibodies/biosynthesis[MESH]
  • |B-Lymphocytes/*immunology/virology[MESH]
  • |COVID-19 Drug Treatment[MESH]
  • |COVID-19/*immunology/mortality/virology[MESH]
  • |Host-Pathogen Interactions/immunology[MESH]
  • |Humans[MESH]
  • |Immunity, Humoral/drug effects[MESH]
  • |Immunoglobulin A/biosynthesis[MESH]
  • |Immunoglobulin G/*biosynthesis[MESH]
  • |Immunoglobulin M/biosynthesis[MESH]
  • |Immunologic Memory[MESH]
  • |SARS-CoV-2/immunology/*pathogenicity[MESH]
  • |Severity of Illness Index[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box